Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences

Matthew L Stoll, Alisa C GotteDepartment of Pediatrics, Division of Rheumatology, UT Southwestern Medical Center, Dallas, TX, USAAbstract: Biologics have advanced the therapy of adult and pediatric arthritis. They have been linked to rare serious adverse outcomes, but the actual risk of these events...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Matthew L Stoll, Alisa C Gotte
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/95739b8c0040412b8576486b3028f6c4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:95739b8c0040412b8576486b3028f6c4
record_format	dspace
spelling	oai:doaj.org-article:95739b8c0040412b8576486b3028f6c42021-12-02T01:04:11ZBiological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences1177-54751177-5491https://doaj.org/article/95739b8c0040412b8576486b3028f6c42008-06-01T00:00:00Zhttp://www.dovepress.com/biological-therapies-for-the-treatment-of-juvenile-idiopathic-arthriti-a1729https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Matthew L Stoll, Alisa C GotteDepartment of Pediatrics, Division of Rheumatology, UT Southwestern Medical Center, Dallas, TX, USAAbstract: Biologics have advanced the therapy of adult and pediatric arthritis. They have been linked to rare serious adverse outcomes, but the actual risk of these events is controversial in adults, and largely unknown in pediatrics. Because of the paucity of safety and efficacy data in children, pediatric rheumatologists often rely on the adult literature. Herein, we reviewed the adult and pediatric literature on five classes of medicines: Tumor necrosis factor (TNF) inhibitors, anakinra, rituximab, abatacept, and tocilizumab. For efficacy, we reviewed randomized controlled studies in adults, but did include lesser qualities of evidence for pediatrics. For safety, we utilized prospective and retrospective studies, rarely including reports from other inflammatory conditions. The review included studies on rheumatoid arthritis and spondyloarthritis, as well as juvenile idiopathic arthritis. Overall, we found that the TNF inhibitors have generally been found safe and effective in adult and pediatric use, although risks of infections and other adverse events are discussed. Anakinra, rituximab, abatacept, and tocilizumab have also shown positive results in adult trials, but there is minimal pediatric data published with the exception of small studies involving the subgroup of children with systemic onset juvenile idiopathic arthritis, in whom anakinra and tocilizumab may be effective therapies.Keywords: juvenile idiopathic arthritis, biologics, rheumatoid arthritis Matthew L StollAlisa C GotteDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 2, Pp 229-252 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Matthew L Stoll Alisa C Gotte Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences
description	Matthew L Stoll, Alisa C GotteDepartment of Pediatrics, Division of Rheumatology, UT Southwestern Medical Center, Dallas, TX, USAAbstract: Biologics have advanced the therapy of adult and pediatric arthritis. They have been linked to rare serious adverse outcomes, but the actual risk of these events is controversial in adults, and largely unknown in pediatrics. Because of the paucity of safety and efficacy data in children, pediatric rheumatologists often rely on the adult literature. Herein, we reviewed the adult and pediatric literature on five classes of medicines: Tumor necrosis factor (TNF) inhibitors, anakinra, rituximab, abatacept, and tocilizumab. For efficacy, we reviewed randomized controlled studies in adults, but did include lesser qualities of evidence for pediatrics. For safety, we utilized prospective and retrospective studies, rarely including reports from other inflammatory conditions. The review included studies on rheumatoid arthritis and spondyloarthritis, as well as juvenile idiopathic arthritis. Overall, we found that the TNF inhibitors have generally been found safe and effective in adult and pediatric use, although risks of infections and other adverse events are discussed. Anakinra, rituximab, abatacept, and tocilizumab have also shown positive results in adult trials, but there is minimal pediatric data published with the exception of small studies involving the subgroup of children with systemic onset juvenile idiopathic arthritis, in whom anakinra and tocilizumab may be effective therapies.Keywords: juvenile idiopathic arthritis, biologics, rheumatoid arthritis
format	article
author	Matthew L Stoll Alisa C Gotte
author_facet	Matthew L Stoll Alisa C Gotte
author_sort	Matthew L Stoll
title	Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences
title_short	Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences
title_full	Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences
title_fullStr	Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences
title_full_unstemmed	Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences
title_sort	biological therapies for the treatment of juvenile idiopathic arthritis: lessons from the adult and pediatric experiences
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/95739b8c0040412b8576486b3028f6c4
work_keys_str_mv	AT matthewlstoll biologicaltherapiesforthetreatmentofjuvenileidiopathicarthritislessonsfromtheadultandpediatricexperiences AT alisacgotte biologicaltherapiesforthetreatmentofjuvenileidiopathicarthritislessonsfromtheadultandpediatricexperiences
_version_	1718403333541068800

Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences

Ejemplares similares